Alkem Laboratories Limited announced on Friday that Chief Executive Officer Dr. Vikas Gupta has resigned to explore new professional opportunities. Dr. Gupta will continue in his position until June 30, 2026, to facilitate a seamless transition of ongoing strategic initiatives and leadership duties. As of now, no successor has been appointed.
The market responded negatively to the news. Alkem’s shares on the National Stock Exchange (NSE) dropped ₹154.50, or 2.80 percent, to ₹5,366 during afternoon trading on Friday, compared to the previous close of ₹5,520.50. There was a conspicuous imbalance in trading, with sell orders outpacing buy orders; 61 percent of queued orders were on the sell side. The stock recorded an intraday low of ₹5,355 but remains above its 52-week low of ₹4,716.20, which was reached in July 2025.
In his resignation letter, Dr. Gupta cited personal and long-term career aspirations for his decision. He expressed that the choice was challenging and noted that his tenure had strengthened Alkem’s market position and advanced its research and development pipeline. He also recognized the support he received from the promoter family and the board during his time at the company.
Alkem Laboratories is part of the Nifty Midcap 50 index and has a total market capitalization of approximately ₹64,111 crore. The stock currently trades at a price-to-earnings ratio of around 27.
This information was published on April 24, 2026.
